Emend

(aprepitant)

ApprovedSmall molecule

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Aprepitant is used to prevent nausea and vomiting caused by chemotherapy and surgery. It works by blocking signals in the brain that trigger these uncomfortable side effects.[2] Emend is currently approved and in use across 22 indications[4].[1]

Emend is one of 521 small molecule programs targeting Gastroparesis. It is currently in Approved.

Indications

122

Total Trials

Active Trials

520

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

GastroparesisApproved

HIV InfectionApproved

Depressive DisorderActive, not recruiting

Post Operative Nausea and VomitingActive, not recruiting

LymphomaActive, not recruiting

DysmenorrheaApproved

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

Chemotherapy-Induced Nausea and VomitingCompleted

Nausea and VomitingCompleted

Opioid DependenceApproved

GastroparesisApproved

Approved

HIV InfectionApproved

Approved

Depressive DisorderApproved

Active, not recruiting

Post Operative Nausea and VomitingApproved

Active, not recruiting

LymphomaPreclinical

Active, not recruiting

DysmenorrheaApproved

Approved

Chronic Obstructive Pulmonary DiseasePreclinical

Active, not recruiting

Chemotherapy-Induced Nausea and VomitingApproved

Completed

Nausea and VomitingApproved

Completed

Opioid DependenceApproved

Approved

Showing 10 of 19 indications

Competition

Competitive Landscape

702 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

3 2

Adenocard

Astellas

Preclinical

2 3

Lexiscan

Astellas

Preclinical

1 4

Voltaren

Novartis

Preclinical

1 5

Vfend

PPrism Pharmaceuticals

Preclinical

—6

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 7

Tianeptine

Pfizer

Preclinical

1 8

Ablavar

LLantheus Medical Imaging

Preclinical

2 9

Liposomal Irinotecan and Apatinib

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Preclinical

1 10

4SCAR T Cells

SShenzhen Geno-Immune Medical Institute

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Nausea and Vomiting

NCT06357234

Q4 2027

N/ARecruiting

Nausea and Vomiting

NCT06080880

Q2 2028

Post-ApprovalNot yet recruiting

Nausea and Vomiting

NCT07371728

Q3 2028

Phase 1Not yet recruiting

Cancer

NCT07662200

Clinical

Trials by Indication[1]

Nausea and vomiting38 trials

Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting

Completed·SSergio Bergese·Phase 4·NCT01474915·122 enrolled

Aprepitant for Postoperative Nausea and Vomiting in Laparoscopic Hysterectomy

Completed·GGachon University Gil Medical Center·N/A·NCT01440673·150 enrolled

Developing Individualized Strategies to Prevent Nausea and Vomiting

Withdrawn·UUniversity of California, San Francisco·N/A·NCT01393288

Show 35 more trials

Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Upper Abdominal Radiotherapy

Completed·UUniversity of Vermont·Phase 2·NCT00970905·52 enrolled

Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric Patients

Completed·UUniversity of Pennsylvania·N/A·NCT00956215·125 enrolled

Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer

Withdrawn·VVanderbilt-Ingram Cancer Center·N/A·NCT00499668

Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy

Terminated·UUniversity of Southern California·N/A·NCT02550119·19 enrolled

Aprepitant Versus Gabapentin Prophylaxis for Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgeries

Completed·—·Phase 2/3·NCT02525848·150 enrolled

Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT01149369·126 enrolled

Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting

Completed·GGynecologic Oncology Associates·Phase 4·NCT01432015·20 enrolled

Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00952341·421 enrolled

Effect of Aprepitant on Post-operative Nausea and Vomiting in Otologic Surgery

Not yet recruiting·SSir Mortimer B. Davis - Jewish General Hospital·Phase 4·NCT07371728·100 enrolled

Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis Surgery

Recruiting·IIWK Health Centre·Phase 2·NCT06357234·100 enrolled

A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

Completed·HHelsinn Healthcare SA·Phase 3·NCT01376297·413 enrolled

Postoperative Nausea and Vomiting: Ramosetron Plus Aprepitant vs Palonosetron Plus Aprepitant

Completed·KKyungpook National University Hospital·N/A·NCT02597907·88 enrolled

Low Dose Olanzapine to the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy in Children and Adolescents

Unknown status·FFederal Research Institute of Pediatric Hematology, Oncology and Immunology·Phase 3·NCT05346731·210 enrolled

Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting

Completed·—·N/A·NCT00659737·115 enrolled

Postoperative Nausea and Vomiting in Laparoscopic Abdominal Surgery

Unknown status·—·Phase 4·NCT05632224·60 enrolled

Oral Aprepitant and Lower Dose Dexamethasone Versus Aprepitant Alone for Preventing Postoperative Nausea and Vomiting (PONV) After Elective Laparoscopic Surgeries

Unknown status·MMain Line Health·N/A·NCT00835965·50 enrolled

Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant

Completed·OOHSU Knight Cancer Institute·N/A·NCT00248547·40 enrolled

Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting

Completed·—·N/A·NCT00717054·115 enrolled

Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00337727·848 enrolled

The Effect of Aprepitant Reducing Postoperative Nausea and Vomiting

Unknown status·—·Phase 4·NCT05772676·400 enrolled

Aprepitant and Granisetron for the Prophylaxis of Radiation Induced Nausea and Vomiting - A Pilot Study

Terminated·SSunnybrook Health Sciences Centre·Phase 2·NCT01183481·19 enrolled

The Effect of Combining Aprepitant With Ondansetron in High-risk Patients for Postoperative Nausea and Vomiting

Completed·YYonsei University·Phase 4·NCT01897337·125 enrolled

Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy

Completed·IIndiana University·Phase 2·NCT02097823·15 enrolled

A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT01732458·229 enrolled

Dual-dose Aprepitant to Reduce Postoperative Nausea and Vomiting After Laparoscopic Bariatric Surgery.

Terminated·IInsel Gruppe AG, University Hospital Bern·Phase 4·NCT05189756·71 enrolled

Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting

Not yet recruiting·CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.·Phase 3·NCT06543966·486 enrolled

Aprepitant PO vs Ondansetron IV for Prevention of Postoperative Nausea and Vomiting

Withdrawn·NNorthwell Health·N/A·NCT00699894

Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer

Completed·TThe First Affiliated Hospital of Zhengzhou University·Phase 4·NCT06697782·600 enrolled

Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting

Completed·QQilu Pharmaceutical (Hainan) Co., Ltd.·Phase 3·NCT06932107·518 enrolled

Aprepitant for Prevention of Postoperative Nausea and Vomiting in Elective Hysterectomy

Terminated·MMayo Clinic·Phase 4·NCT00888329·256 enrolled

Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer

Terminated·GGynecologic Oncology Group·N/A·NCT01275664·4 enrolled

Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis

Completed·VVanderbilt University·N/A·NCT02625181·27,034 enrolled

Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer

Completed·WWake Forest University Health Sciences·Phase 2·NCT01534637·22 enrolled

Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade

Recruiting·UUnknown Sponsor·N/A·NCT06080880·98 enrolled

"Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)"

Completed·—·Phase 3·NCT03219710·240 enrolled

Chemotherapy-induced nausea and vomiting7 trials

Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner Patients

Unknown status·SShanghai Children's Medical Center·N/A·NCT04873284·120 enrolled

Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00080444·50 enrolled

Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.

Completed·SSpanish Breast Cancer Research Group·Phase 4·NCT01298193·212 enrolled

Show 4 more trials

A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT01636947·494 enrolled

Treatment of Chemotherapy-induced Nausea and Vomiting

Completed·UUppsala University Hospital·Phase 2·NCT01101529·90 enrolled

A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01362530·307 enrolled

Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting

Completed·FFirst Affiliated Hospital of Harbin Medical University·Phase 3·NCT02484911·120 enrolled

Major Depressive Disorder5 trials

Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00048594·800 enrolled

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00035048·540 enrolled

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00035282·450 enrolled

Show 2 more trials

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00048607·600 enrolled

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00034983·900 enrolled

Nausea5 trials

Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial

Completed·JJoseph Roscoe·Phase 3·NCT00475085·1,021 enrolled

Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy

Completed· GSK logo

GSK·Phase 2·NCT00169572·492 enrolled

AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors

Completed·PPETHEMA Foundation·Phase 4·NCT00415103·196 enrolled

Show 2 more trials

Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy

Completed·SStony Brook University·Phase 4·NCT03435003·83 enrolled

Multi-day Doses in Prevention of Nausea and Emesis

Completed·UUniversity of Kansas Medical Center·Phase 2·NCT00600353·20 enrolled

Chemotherapy4 trials

Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy

Completed·SSun Yat-sen University·Phase 3·NCT03674294·248 enrolled

Olanzapine Versus Aprepitant Based Antiemetic Regimen for High Emetic Chemotherapy

Unknown status·MMahidol University·Phase 3·NCT03876938·147 enrolled

Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving Chemotherapy

Completed·—·Phase 3·NCT01402024·96 enrolled

Show 1 more trial

Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)

Completed·OOhio State University Comprehensive Cancer Center·N/A·NCT01640340·40 enrolled

48 more indications

Pruritus4 trials

Aprepitant in the Management of Biological Therapies-related Severe Pruritus

Completed·—·Phase 2·NCT01683552·45 enrolled

Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment

Completed·SSun Yat-sen University·Phase 2·NCT02646020·138 enrolled

Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome

Terminated·VVanderbilt University Medical Center·Phase 4·NCT01625455·7 enrolled

Show 1 more trial

Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms

Completed·UUniversity Hospital, Brest·Phase 3·NCT03808805·63 enrolled

Breast Cancer3 trials

Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT00719173·19 enrolled

Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients

Terminated·SS. Maria Hospital, Terni·Phase 3·NCT00869973·580 enrolled

Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer

Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT05841849·1,028 enrolled

Treatment3 trials

Comparison of Adding EMEND to PONV/PDNV Treatment Regimen

Withdrawn·UUniversity of Nebraska·N/A·NCT01186029

Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals

Completed·UUniversity of Pennsylvania·Phase 1·NCT00428519·30 enrolled

Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose

Completed·UUniversity of Pennsylvania·Phase 1·NCT01300988·18 enrolled

Vomiting2 trials

Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC

Completed·CChinese Academy of Medical Sciences·Phase 2·NCT03572829·44 enrolled

Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant

Completed·BBarbara Ann Karmanos Cancer Institute·N/A·NCT00293384·40 enrolled

Withdrawal2 trials

Treatment for Cannabis Withdrawal and Dependence

Completed·TThe Scripps Research Institute·Phase 2·NCT01611948·70 enrolled

Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence

Completed·TThe Scripps Research Institute·Phase 2·NCT02210195·20 enrolled

Ondansetron2 trials

Ondansetron Versus Aprepitant Plus Ondansetron for Emesis

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00954941·100 enrolled

Neurokinin Receptor Antagonist Associated to Ondansetron in PONV

Completed·IInstituto do Cancer do Estado de São Paulo·Phase 4·NCT02357693·90 enrolled

Tics2 trials

Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected Subjects

Completed·UUniversity of Pennsylvania·Phase 1·NCT02154360·12 enrolled

Influence of Antipruritics on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin.

Completed·UUniversitaire Ziekenhuizen KU Leuven·N/A·NCT04399148·13 enrolled

Prophylaxis2 trials

Granisetron Transdermal Patch for Prophylaxis of Delayed CINV

Unknown status·FFudan University·Phase 3·NCT04912271·140 enrolled

Palonosetron Associated to Aprepitant in Prophylaxis of PONV

Unknown status·IInstituto do Cancer do Estado de São Paulo·Phase 4·NCT02431286·90 enrolled

Lung Cancer2 trials

Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy

Unknown status·ZZhejiang University·Phase 2·NCT02445872·80 enrolled

Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer Patients

Terminated·RRadboud University Medical Center·Phase 4·NCT00588835·20 enrolled

PrEP2 trials

A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00945321·42 enrolled

Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT01111851·16 enrolled

Non-Small Cell Lung Cancer2 trials

Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung Cancers

Completed·HHunan Province Tumor Hospital·Phase 3·NCT02161991·244 enrolled

A Study to Evaluate the Efficacy of Anti-emetic Drug Upon the Combination Chemotherapy for Non-small Cell Lung Cancer

Completed·SShiga University··NCT02364804·10 enrolled

Gastric Emptying1 trial

Effects of Aprepitant on Satiation, Gastric Volume, Gastric Accommodation and Gastric Emptying

Completed·MMayo Clinic·Phase 1·NCT02989467·27 enrolled

Glioma1 trial

Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide

Completed·KKaty Peters·Phase 2·NCT01450826·136 enrolled

Heroin Dependence1 trial

Aprepitant Effects in Intravenous Heroin Dependence

Completed·NNYU Langone Health·Phase 1·NCT01527994·64 enrolled

Enhanced Recovery1 trial

Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data

Completed·JJennifer Holder-Murray·Phase 3·NCT04606264·2,977 enrolled

Ovarian Cancer1 trial

Prolonged Emend in a Study (NYU 03-67) of Oxaliplatin and Topotecan in Previously Treated Ovarian Cancer

Withdrawn·NNYU Langone Health·N/A·NCT01017809

Pancreatitis1 trial

A Trial of Aprepitant For Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis

Completed·—·N/A·NCT00736073·73 enrolled

Peripheral Blood Stem Cell Transplantation1 trial

Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation

Completed·WWashington University School of Medicine·Phase 1·NCT00314743·48 enrolled

Carcinoma1 trial

Pharmacokinetic Study of Aprepitant in BEP Treatment of Patients With Testis Carcinoma (A-BEP)

Withdrawn·RRadboud University Medical Center·Phase 4·NCT00429754

Side Effects1 trial

Aprepitant to Mitigate Opioids' Cognitive Side Effects

Unknown status·UUniversity of Arizona·N/A·NCT02226601·50 enrolled

Prurigo1 trial

Topical Aprepitant in Prurigo Patients

Completed· LEO Pharma logo

LEO Pharma·Phase 2·NCT01963793·20 enrolled

Glioblastoma1 trial

A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma

Completed·UUniversity of Ulm·Phase 1/2·NCT02770378·10 enrolled

Acute Myeloid Leukemia1 trial

Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy

Completed·UUniversity Health Network, Toronto·Phase 2·NCT01334086·41 enrolled

TIA1 trial

Differentiating the Effects of Substance P and Beta-endorphin

Completed·—·N/A·NCT01854177·10 enrolled

Germ Cell Tumor1 trial

Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors

Completed·HHoosier Cancer Research Network·Phase 3·NCT00572572·69 enrolled

MPA1 trial

Relative Bioavailability of NXP001 Compared to Emend® in Healthy Volunteers

Completed·NNuformix Technologies Limited·Phase 1·NCT03889366·12 enrolled

Opioid1 trial

Ability of Aprepitant to Block Opioid Reward in Non-Dependent Opiate Abusers

Unknown status·KKarolinska University Hospital·Phase 1·NCT00726960·60 enrolled

Oxycodone1 trial

Aprepitant Effects on Oxycodone Response

Completed·SSharon Walsh·N/A·NCT00999544·9 enrolled

Malignant Tumor1 trial

Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients

Completed·SSichuan Cancer Hospital and Research Institute·Phase 3·NCT06007586·143 enrolled

Adult1 trial

Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Healthy Adult Volunteers

Completed·TThe Hospital for Sick Children·Phase 1·NCT03245918·17 enrolled

ESS1 trial

The Role of Substance P on Perception of Breathlessness During Resistive Load Breathing

Completed·—·N/A·NCT01580423·16 enrolled

PTSD Symptoms1 trial

The Effect of NK1R Antagonism on Alcohol Craving and PTSD Symptoms in Alcohol Dependent Patients With PTSD

Completed·NNational Institute on Alcohol Abuse and Alcoholism (NIAAA)·Phase 2·NCT00896038·58 enrolled

Advanced Cancer1 trial

Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00871910·81 enrolled

Prevention1 trial

Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX

Completed·OOHSU Knight Cancer Institute·Phase 2·NCT00381862·54 enrolled

Carboplatin1 trial

Low Dose Aprepitant for Patients Receiving Carboplatin

Terminated·—·Phase 2·NCT03237611·15 enrolled

Autologous Hematopoietic Stem Cell Transplantation1 trial

A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation

Unknown status·JJun Zhu·Phase 4·NCT02576327·130 enrolled

Dexamethasone1 trial

Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis

Completed·FFudan University·Phase 3·NCT02336750·212 enrolled

Induction Chemotherapy1 trial

Study to Evaluate the Effect of Aprepitant in Children and Adolescents Receiving AML Remission Induction Chemotherapy

Unknown status·DDr Atul Sharma·Phase 3·NCT02979548·116 enrolled

Adolescent1 trial

Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents

Terminated·TThe Hospital for Sick Children·Phase 2·NCT01249001·4 enrolled

Headache1 trial

Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH)

Unknown status·SSun Yat-sen University·Phase 4·NCT02347878·85 enrolled

Pediatric1 trial

A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00819039·98 enrolled

Blood Pressure1 trial

Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure

Completed·VVanderbilt University·N/A·NCT02130687·106 enrolled

Phase 21 trial

Phase 2 Bunionectomy HTX-011 Administration Study

Completed·HHeron Therapeutics·Phase 2·NCT03718039·78 enrolled

Lymphoma1 trial

Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients

Completed·MM.D. Anderson Cancer Center·N/A·NCT00651755·23 enrolled

Heart Failure1 trial

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3

Completed·YYale University·Approved·NCT04649229·46 enrolled

Nausea and Vomiting, Postoperative1 trial

Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients

Completed·CCentre hospitalier de l'Université de Montréal (CHUM)·Phase 3·NCT07248280·260 enrolled

Cancer1 trial

A Pilot Feasibility Study of a Steroid-Sparing Anti-Nausea and Vomiting Regimen With Netupitant/Palonosetron for Patients With Germ Cell Tumours Receiving Multi-Day Cisplatin-Based Chemotherapy at The Ottawa Hospital

Not yet recruiting·OOttawa Hospital Research Institute·Phase 1·NCT07662200·10 enrolled

Unspecified1 trial

A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00990821·188 enrolled

Regulatory

FDA Approval Timeline[5]

Mar 26, 2003

EMEND

NDA NDA021549

Jan 15, 2004

EMEND

NDA NDA021549

Dec 15, 2004

EMEND

NDA NDA021549

Dec 22, 2004

EMEND

NDA NDA021549

Jun 9, 2005

EMEND

NDA NDA021549

Oct 28, 2005

EMEND

NDA NDA021549

Jun 9, 2006

EMEND

NDA NDA021549

Jun 30, 2006

EMEND

NDA NDA021549

Jun 30, 2006

EMEND

NDA NDA021549

Nov 15, 2007

EMEND

NDA NDA021549

Jan 25, 2008

EMEND

NDA NDA022023

Nov 18, 2008

EMEND

NDA NDA021549

Feb 2, 2009

EMEND

NDA NDA021549

Jul 21, 2009

EMEND

NDA NDA021549

Mar 19, 2010

EMEND

NDA NDA021549

Mar 23, 2010

EMEND

NDA NDA022023

Mar 23, 2010

EMEND

NDA NDA022023

Mar 23, 2010

EMEND

NDA NDA022023

Nov 12, 2010

EMEND

NDA NDA022023

Jul 6, 2012

EMEND

NDA NDA022023

Jul 6, 2012

EMEND

NDA NDA021549

Mar 20, 2013

EMEND

NDA NDA022023

Mar 20, 2013

EMEND

NDA NDA021549

Mar 27, 2013

EMEND

NDA NDA021549

Mar 27, 2013

EMEND

NDA NDA022023

Aug 12, 2014

EMEND

NDA NDA021549

Aug 12, 2014

EMEND

NDA NDA022023

Jan 12, 2015

EMEND

NDA NDA021549

Jan 12, 2015

EMEND

NDA NDA022023

Aug 28, 2015

EMEND

NDA NDA021549

Dec 17, 2015

EMEND

NDA NDA207865

Dec 17, 2015

EMEND

NDA NDA207865

Feb 1, 2016

EMEND

NDA NDA022023

Dec 2, 2016

EMEND

NDA NDA022023

May 31, 2017

EMEND

NDA NDA021549

May 31, 2017

EMEND

NDA NDA022023

Aug 9, 2017

EMEND

NDA NDA022023

Nov 9, 2017

CINVANTI

NDA NDA209296

Mar 26, 2018

EMEND

NDA NDA022023

Apr 3, 2018

EMEND

NDA NDA022023

Sep 25, 2019

EMEND

NDA NDA207865

Sep 25, 2019

EMEND

NDA NDA021549

Nov 14, 2019

EMEND

NDA NDA022023

Nov 14, 2019

EMEND

NDA NDA207865

Nov 14, 2019

EMEND

NDA NDA021549

May 2, 2022

EMEND

NDA NDA022023

Sep 16, 2022

APONVIE

NDA NDA216457

Jun 15, 2026

APREPITANT

NDA NDA218754

Sources

References

[1]
ClinicalTrials.gov — 122 trial records for aprepitant. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Emend drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — aprepitant compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for aprepitant. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA218754). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Emend. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Neurokinin 1 Receptor Antagonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Patent Landscape[6]

Patent Cliff

Sep 26, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8258132Sep 26, 2027

9808465Sep 18, 2035

10953018Sep 18, 2035

10624850Sep 18, 2035

9974794Sep 18, 2035

10 more patents

9561229Sep 18, 2035

11744800Sep 18, 2035

11878074Sep 18, 2035

10500208Sep 18, 2035

9974793Sep 18, 2035

12115254Sep 18, 2035

12290520Sep 18, 2035

9974742Sep 18, 2035

12115255Sep 18, 2035

11173118Sep 18, 2035

Emend

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Q2 2028

Q3 2028

Trials by Indication[1]

Nausea and vomiting38 trials

Chemotherapy-induced nausea and vomiting7 trials

Major Depressive Disorder5 trials

Nausea5 trials

Chemotherapy4 trials

Pruritus4 trials

Breast Cancer3 trials

Treatment3 trials

Vomiting2 trials

Withdrawal2 trials

Ondansetron2 trials

Tics2 trials

Prophylaxis2 trials

Lung Cancer2 trials

PrEP2 trials

Non-Small Cell Lung Cancer2 trials

Gastric Emptying1 trial

Glioma1 trial

Heroin Dependence1 trial

Enhanced Recovery1 trial

Ovarian Cancer1 trial

Pancreatitis1 trial

Peripheral Blood Stem Cell Transplantation1 trial

Carcinoma1 trial

Side Effects1 trial

Prurigo1 trial

Glioblastoma1 trial

Acute Myeloid Leukemia1 trial

TIA1 trial

Germ Cell Tumor1 trial

MPA1 trial

Opioid1 trial

Oxycodone1 trial

Malignant Tumor1 trial

Adult1 trial

ESS1 trial

PTSD Symptoms1 trial

Advanced Cancer1 trial

Prevention1 trial

Carboplatin1 trial

Autologous Hematopoietic Stem Cell Transplantation1 trial

Dexamethasone1 trial

Induction Chemotherapy1 trial

Adolescent1 trial

Headache1 trial

Pediatric1 trial

Blood Pressure1 trial

Phase 21 trial

Lymphoma1 trial

Heart Failure1 trial

Nausea and Vomiting, Postoperative1 trial

Cancer1 trial

Unspecified1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Patent Landscape[6]

Related News